Evaluating the COVID-19 vaccination program in Japan, 2021 using the counterfactual reproduction number.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
18 10 2023
18 10 2023
Historique:
received:
17
05
2023
accepted:
13
10
2023
medline:
23
10
2023
pubmed:
19
10
2023
entrez:
18
10
2023
Statut:
epublish
Résumé
Japan implemented its nationwide vaccination program against COVID-19 in 2021, immunizing more than one million people (approximately 1%) a day. However, the direct and indirect impacts of the program at the population level have yet to be fully evaluated. To assess the vaccine effectiveness during the Delta variant (B.1.617.2) epidemic in 2021, we used a renewal process model. A transmission model was fitted to the confirmed cases from 17 February to 30 November 2021. In the absence of vaccination, the cumulative numbers of infections and deaths during the study period were estimated to be 63.3 million (95% confidence interval [CI] 63.2-63.6) and 364,000 (95% CI 363-366), respectively; the actual numbers of infections and deaths were 4.7 million and 10,000, respectively. Were the vaccination implemented 14 days earlier, there could have been 54% and 48% fewer cases and deaths, respectively, than the actual numbers. We demonstrated the very high effectiveness of COVID-19 vaccination in Japan during 2021, which reduced mortality by more than 97% compared with the counterfactual scenario. The timing of expanding vaccination and vaccine recipients could be key to mitigating the disease burden of COVID-19. Rapid and proper decision making based on firm epidemiological input is vital.
Identifiants
pubmed: 37853098
doi: 10.1038/s41598-023-44942-6
pii: 10.1038/s41598-023-44942-6
pmc: PMC10584853
doi:
Substances chimiques
COVID-19 Vaccines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
17762Informations de copyright
© 2023. Springer Nature Limited.
Références
JAMA Netw Open. 2022 Jul 1;5(7):e2220385
pubmed: 35793085
Lancet. 2021 Oct 16;398(10309):1407-1416
pubmed: 34619098
Proc Natl Acad Sci U S A. 2021 Apr 20;118(16):
pubmed: 33811185
Am J Epidemiol. 1997 Nov 15;146(10):789-803
pubmed: 9384199
N Engl J Med. 2022 Feb 24;386(8):744-756
pubmed: 34986294
N Engl J Med. 2021 Aug 12;385(7):585-594
pubmed: 34289274
PLoS Comput Biol. 2021 May 6;17(5):e1008849
pubmed: 33956791
J Epidemiol. 2022 Feb 5;32(2):105-111
pubmed: 34776499
NPJ Digit Med. 2021 May 13;4(1):81
pubmed: 33986465
Lancet Reg Health West Pac. 2021 Sep;14:100224
pubmed: 34345875
Sci Adv. 2021 Feb 3;7(6):
pubmed: 33536223
Emerg Infect Dis. 2022 Sep;28(9):1777-1784
pubmed: 35820166
Euro Surveill. 2021 Jun;26(24):
pubmed: 34142653
Epidemiology. 1995 Mar;6(2):142-51
pubmed: 7742400
Theor Biol Med Model. 2019 Mar 20;16(1):6
pubmed: 30890153
N Engl J Med. 2021 Dec 9;385(24):e85
pubmed: 34706170
Front Public Health. 2022 Jun 10;10:837970
pubmed: 35757644
Can Commun Dis Rep. 2022 Jul 07;48(7-8):292-302
pubmed: 37334255
Int J Infect Dis. 2021 Feb;103:431-438
pubmed: 33388436
Lancet Reg Health Am. 2023 Jan;17:100418
pubmed: 36575682
Science. 2020 Nov 13;370(6518):763-765
pubmed: 33087460
Science. 2021 Feb 26;371(6532):916-921
pubmed: 33479118
Sci Rep. 2021 Jun 29;11(1):13531
pubmed: 34188119
Int J Infect Dis. 2021 Dec;113:47-54
pubmed: 34628020
N Engl J Med. 2022 Apr 21;386(16):1532-1546
pubmed: 35249272
Nat Med. 2021 Dec;27(12):2127-2135
pubmed: 34650248
Am J Epidemiol. 2017 Jul 1;186(1):92-100
pubmed: 28369163
Lancet Infect Dis. 2022 Sep;22(9):1293-1302
pubmed: 35753318
Nat Commun. 2021 Aug 3;12(1):4673
pubmed: 34344871
Expert Rev Vaccines. 2023 Jan-Dec;22(1):90-103
pubmed: 36519401
MMWR Morb Mortal Wkly Rep. 2021 Jan 15;70(2):58-62
pubmed: 33443494
PLoS One. 2021 Jun 10;16(6):e0252468
pubmed: 34111163
Int J Infect Dis. 2020 Apr;93:284-286
pubmed: 32145466
PLoS Med. 2016 Oct 11;13(10):e1002144
pubmed: 27727285
Lancet Reg Health West Pac. 2022 Nov;28:100571
pubmed: 35971514
J Epidemiol. 2021 Jun 5;31(6):387-391
pubmed: 33814508
Viruses. 2020 Jun 30;12(7):
pubmed: 32629880
Epidemiology. 2018 Mar;29(2):215-223
pubmed: 29087989
BMC Public Health. 2022 Jul 15;22(1):1349
pubmed: 35841012
Front Med (Lausanne). 2022 Jul 12;9:937732
pubmed: 35903315
Lancet Reg Health Am. 2022 Jan;5:100085
pubmed: 34746912
Euro Surveill. 2021 Nov;26(47):
pubmed: 34823637
J Clin Med. 2020 Feb 17;9(2):
pubmed: 32079150
Sci Transl Med. 2022 Jun;14(647):eabn9836
pubmed: 35412326
Int J Epidemiol. 1991 Mar;20(1):300-10
pubmed: 2066239
Euro Surveill. 2021 Nov;26(47):
pubmed: 34823641
Int J Infect Dis. 2022 Sep;122:300-306
pubmed: 35688309
Lancet Infect Dis. 2022 Mar;22(3):357-366
pubmed: 34562375
Lancet Digit Health. 2020 Nov;2(11):e622-e628
pubmed: 32905027
Cell Rep Med. 2022 Mar 11;3(4):100583
pubmed: 35480627
BMC Infect Dis. 2022 Dec 12;22(1):933
pubmed: 36510193
Vaccine. 2022 Apr 14;40(17):2506-2513
pubmed: 33958223